Lexington, MA – T2 Biosystems, Inc., a company developing nextgeneration diagnostic products to improve clinical care, today announced that a panel of leading infectious disease and critical care experts have joined the company’s newly

formed Clinical Advisory Board (CAB). The T2 Biosystems CAB members will help prioritize and support the development of the company’s pipeline of diagnostic products for infectious diseases and acute care conditions, including the lead development

application for detection of the fungal infection Candida, using the company’s assay and magnetic biosensor nanotechnology.

Robert C. Moellering, Jr., MD, the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School, will lead T2 Biosystems’ CAB. Other board members include:

• Peter Pappas, MD, Professor, University of Alabama at Birmingham, Principal Investigator, Mycoses Study Group

• Jeff Groeger, MD, Chief of Urgent Care, Memorial Sloan Kettering

• Eric Rosenberg, MD, Co-Director, Microbiology Laboratory, Massachusetts General Hospital

• Lou Rice, MD, Chair, Department of Medicine, Brown University

“The ability to identify rapidly and with certainty the microorganisms which cause serious life-threatening infections has long been an elusive goal. Most currently available systems for “rapid” diagnosis provide answers no sooner than in 12 to 18 hours, and for diseases such as candidemia, many days after the presentation of the illness, making it

necessary to employ empiric initial therapy or no therapy at all,” said Dr. Moellering.

“T2 Biosystems is pioneering a new technology to meet the goal of diagnosis within a one to two hours of the onset of disease. Such an advance would have a significant positive impact on the therapy of numerous infections, allowing early initiation of specific, effective treatment.”

Trained as an infectious diseases specialist, Dr. Moellering has been actively involved in laboratory research for the past 35 years carrying out numerous studies of the mechanism of action and mechanisms of resistance to antimicrobial agents. His work is reported in over 400 publications in scientific journals. He is Editor-in-Chief Emeritus of Antimicrobial Agents and Chemotherapy, Editor of Infectious Disease Clinics of North America, and Associate Editor of the Journal of Infection and Public Health. He served as the Herrman L. Blumgart Professor of Medicine at Harvard Medical School, and

Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel Deaconess Medical Center in Boston through 2005. During that period he was also President and C.E.O. of Harvard Medical Faculty Physicians at BIDMC. Previously, Dr.

Moellering served as Physician-in-Chief at the New England Deaconess Hospital from 1981 until 1996.

“We believe that Dr. Moellering’s longstanding leadership and commitment to the prevention and treatment of infectious diseases will be tremendously valuable in leading our Clinical Advisory Board and guiding T2 Biosystems’ product development

initiatives,” said John McDonough, Chief Executive Officer of T2 Biosystems. “These individuals bring extensive clinical and scientific experience with novel diagnostics and therapeutics. We are honored to have them join our team and look forward to working together to make future advances to the standard of care in diagnostics through the

development of our technology platform.”

About T2 Biosystems, Inc.

T2 Biosystems is disrupting the landscape of clinical diagnostics with its proprietary magnetic biosensor detection platform. The T2Dx platform enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate, and rapid diagnostics results. The company’s products can detect any molecular or immunoassay

target directly from unpurified clinical samples in hospitals, labs, and physicians’ offices. T2 Biosystems is located in Lexington, Massachusetts. For more information, please visit the company’s website at www.t2biosystems.com.